Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (10552)	6/27/1999 9:05:00 AM
From: Robert K.	Respond to of 17367

Chrisy, whether or not it is a stupid investment only time will tell. I do believe that one should generally invest in what what knows. I do feel that most investors have no clue as to what their investments are really about. Understanding about a investment does not make one successful at it. I do think that understanding it does increase your odds of success vs failure. Each situation is different for each person. If you want to get a feel for what the science says about what xoma is doing, I suggest you read medline & input bpi. The more you read the more you will understand. Success is never assured. I hope that helps. Bluegreen>"The activation of phagocytes by lipopolysaccharide (LPS) has been implicated in the pathogenesis of Gram-negative sepsis." That comment hits to the heart of the Heyderman paper on bpi21 vs activation. Hmmmm. What do you think? All IMO. Consider as worthless. Standard K disclaimers..